Welcome to Iaso Therapeutics
Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.
Mutant Qβ Platform
Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, tetanus toxoid, and cross reactive material-197 (CRM-197).

Company News
Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing
Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.
Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research
The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the development of novel technologies for [...]